|
 |
Dr Anji Reddy: People's Doctor
 |
|
| When Dr Anji Reddy talks pharmaceuticals, people listen. He proved to the world that pharmaceuticals can be a great business, that one can make money selling affordable drugs. Almost single handedly, he brought India the epithet of bulk drugs capital |
|
 |
|
|
| |
| CliniRx supports multinational clinical trials:
|
|
| Geared up by the increasing rate of outsourcing by the pharma companies, the clinical research market has been able to survive the recession. Therefore, more and more Indian clinical research companies are going global and expanding their service |
|
|
|
|
| |
| Simcere names Dr Yehong Zhang as President
|
|
| Dr Zhang has over 18 years of experience in the healthcare industry, most recently serving as a Senior Healthcare Practice Leader in McKinsey's China office focusing on systemic issues impacting the healthcare industry |
|
|
|
|
| |
| Veeda appoints Mr Venu Madhav as COO for India
|
|
| Mr Madhav brings in 19 years of experience in diverse areas of clinical research. He has been associated with reputed companies such as Ranbaxy and Sun Pharma especially in the growth period of these organizations |
|
|
|
|
| |
| TBVI is developing booster BCG vaccines for TB
|
|
| Tuberculosis or TB is the oldest disease known to science. Today, it is one of the biggest killers affecting almost two billion people. Far from being a disease of the past, around one-third of the earths population is infected |
|
|
|
|
| |
|
|
| |
|
|
| |
| GSK Japan gets new President
|
|
| GlaxoSmithKline has appointed Mr Philippe Fauchet as the President of GSK Japan. Mr Fauchet joins GSK from Sanofi Aventis where he was Senior Vice President, Business Development |
|
|
|
|
| |
| Daniel Vasella to leave Novartis, Joe Jimenez new CEO
|
|
| After 14 years as the CEO, Daniel Vasella is stepping down as Novartis CEO. He is being replaced by Joe Jimenez, the current head of Novartis' pharma division. Dr. Daniel Vasella served 14 years as CEO and 11 years as Chairman and CEO |
|
|
|
|
| |
|
|
| More |
